Canopy Growth (NASDAQ:CGC - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01, Zacks reports. Canopy Growth had a negative net margin of 195.76% and a negative return on equity of 88.54%. The company had revenue of $52.98 million during the quarter, compared to the consensus estimate of $64.98 million.
Canopy Growth Stock Up 19.0%
Canopy Growth stock opened at $1.25 on Friday. The company has a market capitalization of $256.44 million, a P/E ratio of -0.41 and a beta of 0.67. The company has a quick ratio of 2.10, a current ratio of 3.12 and a debt-to-equity ratio of 0.62. The firm has a 50 day moving average price of $1.23 and a 200-day moving average price of $1.36. Canopy Growth has a twelve month low of $0.77 and a twelve month high of $7.21.
Analyst Upgrades and Downgrades
Separately, Piper Sandler reaffirmed an "underweight" rating on shares of Canopy Growth in a report on Friday, May 30th.
Get Our Latest Report on CGC
Institutional Trading of Canopy Growth
A hedge fund recently raised its stake in Canopy Growth stock. Goldman Sachs Group Inc. boosted its position in Canopy Growth Corporation (NASDAQ:CGC - Free Report) by 64.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 330,278 shares of the company's stock after acquiring an additional 129,620 shares during the period. Goldman Sachs Group Inc. owned 0.18% of Canopy Growth worth $301,000 at the end of the most recent reporting period. Institutional investors own 3.33% of the company's stock.
Canopy Growth Company Profile
(
Get Free Report)
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Canopy Growth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list.
While Canopy Growth currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.